Cypress Capital Group
HQL icon

Cypress Capital Group’s abrdn Life Sciences Investors HQL Stock Holding History

Cypress Capital Group’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-12,140
Closed -$252K – 209
2014
Q2 		$252K Buy
+12,140
New +$255K 0.06% 192

Other funds holding HQL

Needham Investment Management
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Advisors Asset Management
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
UBS
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Virtu KCG Holdings
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Cypress Capital Group's HQL Position: Q3 2014 in Review

Cypress Capital Group sold out of abrdn Life Sciences Investors (HQL) in Q3 2014, closing a stake of 12,140 shares — an estimated $252K sold.

Cypress Capital Group first reported a position in HQL in Q2 2014 and held it in 1 quarter. The position peaked at $252K in Q2 2014. 49 funds tracked by Wall St. Rank hold HQL as of Q3 2014.

  • Cypress Capital Group reported no remaining abrdn Life Sciences Investors position as of Q3 2014 after selling out during the quarter.
  • Cypress Capital Group sold 12,140 abrdn Life Sciences Investors shares in Q3 2014, an estimated $252K.
  • Cypress Capital Group first reported a position in abrdn Life Sciences Investors in Q2 2014 and held it in 1 quarter.
  • Cypress Capital Group's abrdn Life Sciences Investors position peaked at $252K in Q2 2014.
  • 49 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2014.

Based on Cypress Capital Group's 13F filing for Q3 2014, filed 18 Nov 2014.